The treatment of primary central nervous system lymphoma in 122 immunocompetent patients

The objective of this study was to evaluate the clinical outcome of a population‐based cohort of immunocompetent patients with primary central nervous system lymphoma (PCNSL) treated with 3 different strategies over 13 years.

[1]  E. Thiel,et al.  Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan , 2004, Neurology.

[2]  J. Armitage,et al.  Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Batchelor,et al.  Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Blay,et al.  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Deangelis,et al.  Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Blay,et al.  A multicenter study of treatment of primary CNS lymphoma , 2002, Neurology.

[7]  A. López-Guillermo,et al.  Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Hoang-Xuan,et al.  Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Deangelis,et al.  Treatment for primary CNS lymphoma: the next step. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Dichgans,et al.  PCV salvage chemotherapy for recurrent primary CNS lymphoma , 2000, Neurology.

[11]  M. Barton,et al.  Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Y. Shibamoto,et al.  Primary central nervous system lymphoma in Japan: a nationwide survey. , 1999, International journal of radiation oncology, biology, physics.

[15]  M. Reni,et al.  Second-line treatment for primary central nervous system lymphoma , 1999, British Journal of Cancer.

[16]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Corry,et al.  Primary central nervous system lymphoma: age and performance status are more important than treatment modality. , 1998, International journal of radiation oncology, biology, physics.

[18]  J. Blay,et al.  High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Deangelis,et al.  Long-term survival in primary CNS lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Reni,et al.  Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. O'fallon,et al.  Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? , 1995, International journal of radiation oncology, biology, physics.

[22]  P. Burger,et al.  Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma , 1994, Neurology.

[23]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[24]  National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. , 1982, Cancer.

[25]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .